DelveInsight is a prominent provider of valuable research within biotech and pharmaceutical industries. It offers analytical reports in such Health Care sectors as gene therapy, medical oncologic therapy, Active Pharmaceutical Ingredient (API) manufacturing, stem cell medication, biosimilars, orphan drugs and others. The expertise includes:
- Company’s profile and licensing data;
- New technology studies;
- Biologic benchmarking;
- Treatment modality analysis;
- Competitive landscape;
- Product assessment; etc.
This knowledge is essential for Generic and Drug Development companies, which also receive drug sales estimation and product performance forecasts.
DelveInsight reconciles customers need for information and for innovative approaches in business development. Consequently, the obtained data is turned into strategic design, partner up opportunities, profit earning capacity of the business. DelveInsight analysts assist pharma enterprises in launching new products and marketing development of existing pharmaceutics.
Publications found:
6,889
Sort by:
Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022
US$ 2,500.00
This report can be delivered to the clients within 3-4 working days DelveInsight’s, “Cyclin-dependent-kinase-inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 40+ com...
January 2022
150 pages
VAP-1 Inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “VAP-1 Inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline dru...
January 2022
60 pages
Anti-CD22 Therapies - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Anti-CD22 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline...
January 2022
60 pages
Anti-CD30 Therapies - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Anti-CD30 Therapies - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline...
January 2022
60 pages
AXL Kinase Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “AXL Kinase Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipelin...
January 2022
60 pages
LRRK2 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “Leucine-Rich Repeat Kinase (LRRK)-2 Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 8+...
January 2022
60 pages
TGFb inhibitors - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 24 Hours DelveInsight’s, “TGF-Beta Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline...
January 2022
60 pages
TIM-3 Inhibitor - Pipeline Insight, 2022
US$ 1,500.00
This report can be delivered to the clients within 48 Hours DelveInsight’s, “TIM-3 Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline dru...
January 2022
60 pages
